Sort
82,697 grants matching “vaccine development”
Therapeutics for Inpatients with COVID-19 (TICO) Trial
$2,357,228Laura McNay · National Institute Of Allergy And Infectious Diseases · Y01 · FY2021 · AI
RNA-based HIV-1 chimera vaccines encoding a trimerizing host self-protein protomer linked to a viral MPER-TM segment
$2,356,969Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2024 · AI
Malaria Vaccine: Pfs25-rEPA
$2,356,798Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Pitt-Ohio State Clinical Trials Unit
$2,355,644John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2022 · AI
Robust T-cell Immunity to Influenza in Human Populations
$2,355,398Jack A Gorski · Versiti Wisconsin, Inc. · U19 · FY2006 · AI
BONE MARROW GRAFTING FOR LEUKEMIA AND LYMPHOMA
$2,355,342Stanford University · P01 · FY2000 · CA
Providence/Boston Center for AIDS Research (CFAR)
$2,355,280Susan Cu-Uvin · Miriam Hospital · P30 · FY2021 · AI
Maternal immune protection against congenital CMV infection
$2,355,000Sallie R. Permar · Duke University · DP2 · FY2012 · HD
IMPACTA PERU CLINICAL TRIALS UNIT
$2,354,219Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2014 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS
$2,354,037Richard Webby · St. Jude Children'S Research Hospital · N01 · FY2019 · AI
Maternal Omics to Maximize Immunity
$2,353,983Douglas A Lauffenburger · Massachusetts Institute Of Technology · U19 · FY2025 · AI
Maternal Omics to Maximize Immunity
$2,353,983Douglas A Lauffenburger · Massachusetts Institute Of Technology · U19 · FY2024 · AI
Maternal Omics to Maximize Immunity
$2,353,983Douglas A Lauffenburger · Massachusetts Institute Of Technology · U19 · FY2022 · AI
Maternal Omics to Maximize Immunity
$2,353,983Douglas A Lauffenburger · Massachusetts Institute Of Technology · U19 · FY2023 · AI
Nonhuman Primate (NHP) Core Functional Genomics Laboratory for AIDS Vaccine Research and Development
$2,353,974Michael Gale · University Of Washington · N01 · FY2019 · AI
Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens
$2,353,868Christopher Parks · International Aids Vaccine Initiative · P01 · FY2019 · AI
Dendritic cells heterogeneity and function
$2,353,837Roxane Tussiwand · National Institute Of Dental & Craniofacial Research · ZIA · FY2025 · DE
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection
$2,351,111Raymond T Chung · Massachusetts General Hospital · U19 · FY2014 · AI
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities
$2,350,747Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2024 · AI
SPORE in Skin Cancer
$2,350,000John Munn Kirkwood · University Of Pittsburgh At Pittsburgh · P50 · FY2017 · CA
Discovery of Chemical Probes and Therapeutic Leads, Phase II
$2,349,582Joseph M Fox · University Of Delaware · P20 · FY2020 · GM
Nano-optical reporters of dynamic mechanotransduction in the immune system
$2,347,500Jennifer A. Dionne · Stanford University · DP2 · FY2019 · AI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
$2,346,815Daniel William Cramer · Brigham And Women'S Hospital · P50 · FY2006 · CA
SPORE in Brain Cancer
$2,346,429Darell D Bigner · Duke University · P50 · FY2008 · CA
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,346,019Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2020 · DA